Eli Lilly and Company (NYSE:LLY) Shares Purchased by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV increased its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 12.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,605 shares of the company’s stock after buying an additional 7,716 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Eli Lilly and were worth $19,938,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Congress Wealth Management LLC DE acquired a new stake in Eli Lilly and in the fourth quarter valued at $600,000. Envestnet Asset Management Inc. boosted its holdings in shares of Eli Lilly and by 21.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 420,186 shares of the company’s stock valued at $116,064,000 after buying an additional 73,713 shares in the last quarter. Modera Wealth Management LLC raised its stake in Eli Lilly and by 1.6% during the 4th quarter. Modera Wealth Management LLC now owns 3,471 shares of the company’s stock worth $959,000 after acquiring an additional 55 shares in the last quarter. Arete Wealth Advisors LLC lifted its position in Eli Lilly and by 37.5% in the fourth quarter. Arete Wealth Advisors LLC now owns 1,887 shares of the company’s stock valued at $520,000 after acquiring an additional 515 shares during the last quarter. Finally, Bridgewater Advisors Inc. purchased a new position in shares of Eli Lilly and during the fourth quarter worth about $227,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LLY shares. JPMorgan Chase & Co. raised their price target on Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. UBS Group raised their price objective on shares of Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 27th. Barclays upped their target price on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, July 7th. SVB Leerink started coverage on Eli Lilly and in a report on Monday, May 23rd. They set an “outperform” rating and a $341.00 price target on the stock. Finally, Mizuho increased their price objective on Eli Lilly and from $315.00 to $356.00 in a research report on Monday, May 2nd. Three research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and presently has a consensus rating of “Moderate Buy” and an average target price of $317.00.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of the stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now owns 8,136 shares in the company, valued at approximately $2,477,412. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 118,856 shares of the company’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $302.73, for a total transaction of $35,981,276.88. Following the transaction, the insider now owns 105,353,810 shares in the company, valued at $31,893,758,901.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Alonzo Weems sold 656 shares of the stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the completion of the sale, the senior vice president now directly owns 8,136 shares of the company’s stock, valued at $2,477,412. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,114,591 shares of company stock worth $355,690,328. 0.12% of the stock is owned by company insiders.

Eli Lilly and Stock Down 1.2 %

Shares of Eli Lilly and stock opened at $310.31 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. The business has a 50-day moving average price of $315.62 and a 200 day moving average price of $292.52. Eli Lilly and Company has a fifty-two week low of $220.20 and a fifty-two week high of $335.33. The firm has a market cap of $294.85 billion, a P/E ratio of 49.49, a P/E/G ratio of 2.14 and a beta of 0.35.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). The business had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.87 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 7.96 earnings per share for the current fiscal year.

Eli Lilly and Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be given a $0.98 dividend. This represents a $3.92 annualized dividend and a yield of 1.26%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is 62.52%.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.